Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
Briefly, mice were individually housed in standard laboratory cages
doi:10.1016/j.nbd.2024.106684 39
Other research highlights: 30% of GLP-1 users tested positive for SIBO or IMO even after accounting for diabetes (5) GLP-1 medicines caused microbiome changes and altered metabolism in mice (6) GLP-1 medicines tested in humans only had noticeable microbiome changes by 48 weeks (7) Despite not necessarily having slower gut motility, one study found that 88.9% of obese patients had SIBO (8) A meta analysis of people with IBS symptoms, found that up to 78% of people had SIBO, many of whom were undiagnosed (9) Overall, Sun and colleagues (1) could not prove a mechanistic link between GLP-1 medications and SIBO, however they did find that SIBO was twice as likely in GLP-1 users
Neuroprotection: GLP-1s cross the blood-brain barrier and act on microglia, supporting brain and mood health
By covalent (albiglutide, dulaglutide) or no-covalent (semaglutide) coupling to larger molecules with slow clearance, analogs with even more prolonged activity have been produced so that there are now several once-weekly agonists on the market
US$ 25.28
US$ 26.69
US$ 27.40
US$ 20.78
US$ 28.69
US$ 23.42
US$ 27.66
US$ 23.91
US$ 28.19
US$ 26.81
US$ 22.73
US$ 21.18
